Clinical Trial Update: Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of 400 μg aclidinium bromide taken twice daily versus placebo in adults with moderate to severe chronic obstru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: COPD | Phase 3 | Status: COMPLETED